Groundbreaking Human Bird Flu Vaccine Trial Commences Across UK
A pioneering phase 3 clinical trial has been initiated to evaluate a novel vaccine designed to protect humans against bird flu, with approximately 4,000 participants set to be recruited, the majority within the United Kingdom. This landmark study represents a proactive effort to enhance pandemic readiness as the A(H5N1) strain of avian influenza continues to evolve and spread among animal populations globally.
Extensive Recruitment Targets High-Risk Groups
The trial will involve around 3,000 UK patients, with half of these individuals being over the age of 65, receiving vaccinations at 26 distinct sites spread across England and Scotland. Researchers are particularly encouraging poultry farmers and those who maintain close contact with birds to participate, given their elevated exposure risk. An additional 1,000 participants will be enrolled from the United States, bringing the total to roughly 4,000 volunteers.
Dr. Rebecca Clark, the trial's national coordinating investigator based at Layton Medical Centre in Blackpool, emphasised the strategic importance of this initiative. "We know that the A(H5N1) strain is evolving and spreading across animal species, and though it does not yet move easily between humans, we have to treat human-to-human transmission as a real possibility," she stated. "This trial is our proactive attempt to shield against that possibility, and any future pandemic that could emerge from it."
Advanced mRNA Technology at the Core
The experimental vaccine, designated mRNA-1018 and developed by the pharmaceutical company Moderna, utilises messenger RNA (mRNA) technology similar to that employed in several Covid-19 vaccines. This innovative approach instructs the body to produce specific proteins from the target virus, thereby training the immune system to recognise and mount a rapid defensive response upon future exposure to the illness.
Dr. Hiwot Hiruy, Senior Director of Clinical Development at Moderna, provided insights from earlier trial phases. "Early trials of the jab found it to be generally well tolerated, with most of the side-effects being mild to moderate, and there were no safety concerns," she reported. "We also saw that mRNA-1018 induced a strong immune response, and that we were able to detect that immune response as early as seven days after the first injection, and the immune response persisted."
Addressing a Growing Global Threat
The A(H5N1) bird flu viruses first emerged in southern China in 1996, with initial human infections documented a year later. In recent years, this strain has caused widespread outbreaks in birds worldwide and has also affected other animals, including mink, marine mammals, and, more recently, dairy cows in the United States. Since 2024, there have been 116 confirmed human cases globally, nearly all linked to direct contact with infected animals.
Dr. Richard Pebody, Director of Epidemic and Emerging Infections at the UK Health Security Agency (UKHSA), highlighted the persistent threat. "We clearly don't know when the next pandemic is going to be, we obviously don't know what it's going to be caused by, but what we do know is that a flu pandemic is the most likely future pandemic," he remarked. While the current risk to humans remains low, Dr. Pebody cautioned that the virus "continues to evolve," and the UKHSA remains vigilant for any potential adaptation enabling person-to-person spread.
Enhancing National Pandemic Preparedness
This seven-month study, sponsored by Moderna and backed by the National Institute for Health and Care Research (NIHR), will administer two vaccine doses to participants three weeks apart. Given the absence of widespread bird flu in human populations, researchers will use immune response metrics as an early indicator of the vaccine's likely efficacy.
Dr. Clark noted the community-focused approach of the trial: "With recruitment sites across the country, we have shifted from traditional hospital settings into the heart of our communities, helping ensure the research can be carried out across a range of locations and populations. This work is an important part of strengthening our understanding of how we can respond to emerging public health threats and improve pandemic preparedness for the future."
Dr. Hiruy further underscored the advantages of mRNA technology, noting it allows for faster production and rapid adjustment to emerging viral strains compared to more traditional vaccine platforms. While the UK government secured over five million doses of an H5 influenza vaccine based on conventional technology in late 2024 to bolster stockpiles, this new mRNA vaccine represents an "additional tool in pandemic preparedness," according to Dr. Hiruy.
Dr. Pebody concluded, "This important initiative to trial a new mRNA pandemic influenza vaccine is a key step towards further strengthening our ability to protect people against future influenza pandemics." The trial marks a significant advancement in global health security efforts against the ever-present threat of avian influenza.
